Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design

IMPORTANCE: Clinical trials are testing vaccines that target human papillomavirus 16 (HPV-16) oncoproteins for the treatment of cervical cancer regardless of the HPV type of the tumor. For patients with HPV-18–positive cancers, this strategy relies on cross-reactivity of HPV-16–reactive T cells agai...

Descripción completa

Detalles Bibliográficos
Autores principales: Helman, Sarah R., Stevanović, Sanja, Campbell, Tracy E., Kwong, Mei Li M., Doran, Stacey L., Faquin, William C., Hinrichs, Christian S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324313/
https://www.ncbi.nlm.nih.gov/pubmed/30646017
http://dx.doi.org/10.1001/jamanetworkopen.2018.0706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324313/
https://www.ncbi.nlm.nih.gov/pubmed/30646017
http://dx.doi.org/10.1001/jamanetworkopen.2018.0706

Ejemplares similares